Official PDF Translation•Acta Biochimica et Biophysica Sinica
Glycolysis Reprogramming Predicts Poor Prognosis and Drives Therapy Resistance via CLN6 in Lethal Prostate Cancer
Authors: CAI Zhouda; LU Jianming; MO Shanshan; LIU Jipu; ZHONG Chuanfan; WU Yongding; ZOU Fen; YE Jianheng; HAN Zhaodong; LIANG Yuxiang; ZHANG Le; LIU Fengping; ZHONG Weide
• Elevated glycolysis activity is associated with poor survival in lethal prostate cancer.
• A six-gene glycolysis-based prognostic score (GLY score) effectively stratifies patient risk.
• Enzalutamide-resistant prostate cancer cells exhibit heightened glycolysis, and 2-DG inhibition restores drug sensitivity.
• CLN6 knockdown reduces glycolytic activity and cell proliferation, highlighting its potential as a therapeutic target.